Novartis has been making consistent moves in the bio-tech sector, pushing its stock value on a progressive path. Wall Street Zen’s recent downgrade of the stock to ‘Hold’ from ‘Buy’, contrary to certain optimistic views about the company's potential for long-term investment hold.
Morgan Stanley upgraded Novartis due to stock pullback and the launch of Rhapsido. Multiple firms like
First Pacific Financial, Ethic Inc., and Archford Capital Strategies LLC are increasing their stock positions in Novartis signaling market confidence. There has been positive growth with Novartis reaching new 52-week high despite a minor fall due to generic dent in blockbuster heart drug. Furthermore, Novartis US Stock rises with reports of a possible White House pricing deal. The company's 24.5% surge indicates positive indicators, however, questions remain if there's still room for more growth.
Goldman Sachs suggests contrary views with Novartis being overvalued. The company's value has been evaluated in light of a 17% Return Year-to-Date. Bullish sentiment is high with firms like
JP Morgan and Morgan Stanley upgrading Novartis to Overweight. Currently, Barnes is preparing for Q3 earnings announcement as Jim Cramer steps in to endorse Novartis as a 'buy'.
Novartis Stocks News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 03 Jan 2026 08:49:36 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor 0
